Exchange: NASDAQ·Updated 03:34 PM EDT
RNAC logo

RNACSelecta Biosciences Inc

$10.32
$0.10
(0.96%)
Today
EarningsAug 6
Mkt Cap$306.16M
Vol98,686.00
News
all
press releases
New Strong Sell Stocks for July 1st
CZR, RNAC and NSP have been added to the Zacks Rank #5 (Strong Sell) List on July 1, 2026.
Zacks
News Placeholder
More News
News Placeholder
Kiniksa Pharmaceuticals International, plc (KNSA) Surges 5.4%: Is This an Indication of Further Gains?
Kiniksa Pharmaceuticals International, plc (KNSA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
News Placeholder
These Are the Stocks Traders Are Watching into the Close
As the market enters the final stretch of trading, one story is dominating virtually every trading desk on Wall Street: the historic debut of SpaceX. The company's long-awaited public offering has generated extraordinary volume, massive investor interest, and renewed enthusiasm across multiple high-growth sectors including space infrastructure, artificial intelligence, biotechnology, and advanced communications. $NTHI, $SPCX, $ELVN, $POET, $RNAC, $ALOY
24-7 Market News
News Placeholder
New Partnership Gives Cartesian Therapeutics Another Shot At Autoimmune Disease Market
Cartesian Therapeutics gains after licensing an in vivo CAR-T platform from WestGene, with a myasthenia gravis trial planned for 2026.read more...
Benzinga
News Placeholder
Wedbush Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)
Wedbush restated an "outperform" rating and set a $38.00 price objective on shares of Cartesian Therapeutics in a research report on Friday...
MarketBeat
News Placeholder
Cartesian Therapeutics (NASDAQ:RNAC) Posts Quarterly Earnings Results
Cartesian Therapeutics (NASDAQ:RNAC - Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($1.46) earnings per share for the quarter, missing analysts' consensus...
MarketBeat
News Placeholder
Cartesian Therapeutics, Inc. (RNAC) Reports Q1 Loss, Lags Revenue Estimates
Cartesian Therapeutics, Inc. (RNAC) delivered earnings and revenue surprises of -73.81% and -81.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
News Placeholder
Cartesian Therapeutics (RNAC) Projected to Post Earnings on Thursday
Cartesian Therapeutics (NASDAQ:RNAC) will be releasing earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-selecta-biosciences-inc-stock-1...
MarketBeat
News Placeholder
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Cartesian Therapeutics, Inc. (NASDAQ:RNAC - Get Free Report) has received an average rating of "Moderate Buy" from the six brokerages that are covering the stock, Marketbeat reports. One equities...
MarketBeat
News Placeholder
Cartesian Therapeutics, Inc. (RNAC) Soars 10.3%: Is Further Upside Left in the Stock?
Cartesian Therapeutics, Inc. (RNAC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
<
1
2
...
>

Advertisement|Remove ads.